Cangrelor

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Cangrelor, sold under the brand name Kengreal among others, is a P2Y 12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y 12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. It is authorized as a generic medication.

Cangrelor, sold under the brand name Kengreal among others, is a P2Y 12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y 12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. It is authorized as a generic medication.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1329245666 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

10 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.